AbbVie Long-Term Investments 2010-2024 | ABBV

AbbVie long-term investments from 2010 to 2024. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.
  • AbbVie long-term investments for the quarter ending September 30, 2024 were $0.267B, a 2.91% decline year-over-year.
  • AbbVie long-term investments for 2023 were $0.304B, a 26.14% increase from 2022.
  • AbbVie long-term investments for 2022 were $0.241B, a 13% decline from 2021.
  • AbbVie long-term investments for 2021 were $0.277B, a 5.46% decline from 2020.
AbbVie Annual Long-Term Investments
(Millions of US $)
2023 $304
2022 $241
2021 $277
2020 $293
2019 $93
2018 $1,420
2017 $2,090
2016 $1,783
2015 $145
2014 $92
2013 $118
2012 $119
2011 $229
2010 $137
2009 $
AbbVie Quarterly Long-Term Investments
(Millions of US $)
2024-09-30 $267
2024-06-30 $272
2024-03-31 $305
2023-12-31 $304
2023-09-30 $275
2023-06-30 $288
2023-03-31 $257
2022-12-31 $241
2022-09-30 $235
2022-06-30 $244
2022-03-31 $260
2021-12-31 $277
2021-09-30 $272
2021-06-30 $266
2021-03-31 $305
2020-12-31 $293
2020-09-30 $246
2020-06-30 $225
2020-03-31 $78
2019-12-31 $93
2019-09-30 $131
2019-06-30 $1,473
2019-03-31 $1,477
2018-12-31 $1,420
2018-09-30 $1,463
2018-06-30 $1,505
2018-03-31 $2,057
2017-12-31 $2,090
2017-09-30 $1,971
2017-06-30 $2,052
2017-03-31 $2,123
2016-12-31 $1,783
2016-09-30 $1,378
2016-06-30 $1,400
2016-03-31 $387
2015-12-31 $145
2015-09-30 $74
2015-06-30 $134
2015-03-31 $93
2014-12-31 $92
2014-09-30 $124
2014-06-30 $130
2014-03-31 $119
2013-12-31 $118
2013-09-30 $123
2013-06-30 $121
2013-03-31 $118
2012-12-31 $119
2012-09-30 $203
2012-06-30 $237
2012-03-31 $221
2011-12-31 $229
2011-09-30
2011-06-30
2011-03-31
2010-12-31 $137
2009-12-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $294.353B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94